The intensification of upstream bioprocessing sounds daring, as though it were equivalent to flooring a car’s accelerator pedal and pushing the tachometer into the red zone. But with the right ...

Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Modern upstream bioprocessing relies on tighter control strategies as regulators and manufacturers push toward real-time decision making. Yet the inherent variability of living cell systems makes it ...